- 02 Nov 2023
First-line treatment with dabrafenib plus trametinib is significantly more likely to achieve a response than chemotherapy for children with low-grade glioma carrying a BRAF V600 alteration, indicates a phase 2 trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. …more
- 26 Oct 2023
DOPA decarboxylase could be an effective biomarker for dopaminergic dysfunction, detecting early and preclinical Lewy body disease and atypical Parkinsonian disorders, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. …more
- 19 Oct 2023
To prevent systemic lupus erythematosus flare, tapering of corticosteroid or immunosuppressive therapy is best done when patients are in complete remission and have maintained stable disease for at least 6 months, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. …more
- 12 Oct 2023
Phase 1–2 trial findings indicate that the cereblon E3 ubiquitin ligase modulator mezigdomide, given in combination with dexamethasone, could offer a novel oral regimen for patients with heavily pretreated multiple myeloma.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. …more
All articles loaded
No more articles to load
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.showcase
MEET THE SENIOR TEAM
Lynda Williams
medwireNews Deputy Bureau Chief
